Ascending Aorta Replacement During Aortic Valve Surgery
When performing aortic valve replacement or other cardiac surgery, concomitant ascending aorta replacement is indicated at ≥45 mm in patients with bicuspid aortic valve (BAV), and should be considered at ≥45 mm (otherwise ≥50 mm) in patients with tricuspid aortic valve (TAV) disease when surgical risk is low. 1
Bicuspid Aortic Valve (BAV) Patients
The 2024 ESC Guidelines provide the most current and definitive thresholds for BAV-associated aortopathy:
Class I Indication (Mandatory)
- ≥45 mm: Aortic root or ascending aortic diameter when surgical aortic valve replacement is scheduled 1
This represents a firm, evidence-based threshold that applies regardless of other risk factors when the patient is already undergoing valve surgery. The 2022 ACC/AHA guidelines similarly recommend concomitant aortic replacement at ≥45 mm in BAV patients undergoing valve surgery 2.
Additional Considerations for BAV
For isolated aortic surgery (without valve replacement), higher thresholds apply:
- ≥50 mm with risk factors (coarctation, hypertension, family history of dissection, growth >3 mm/year) 1
- ≥55 cm without additional risk factors 2
Tricuspid Aortic Valve (TAV) Patients
The 2024 ESC Guidelines differentiate based on surgical risk:
Class IIa Recommendation
- ≥45 mm: In low surgical risk patients undergoing tricuspid aortic valve surgery, ascending aorta or root replacement should be considered 1
- ≥50 mm: Alternative threshold when not meeting low-risk criteria 1
For isolated ascending aortic aneurysms without valve disease:
Critical Nuances and Pitfalls
The BAV vs. TAV distinction is crucial. BAV patients have inherently different aortic pathology with higher dissection risk at smaller diameters. The 2008 ACC/AHA guidelines 3 recommended 5.0 cm for BAV, but this has been lowered to 4.5 cm in contemporary guidelines when valve surgery is already planned, reflecting evolving understanding of BAV aortopathy risk.
Measurement technique matters. Confirm measurements >50 mm with CT or MRI if initially detected by echocardiography 1. Different imaging modalities can yield different measurements, and surgical decisions require accurate sizing.
Growth rate is a red flag. Any increase >3 mm/year warrants annual surveillance and lowers surgical thresholds 1. This rapid expansion indicates unstable aortic wall pathology.
The "aortic size paradox" exists. Research demonstrates that many acute aortic dissections occur at diameters below current surgical thresholds 4, 5, 6. One study found 15-year freedom from aortic complications was only 43% in patients with 4.5-4.9 cm aortas left unrepaired during AVR 4. This supports the lower thresholds recommended in current guidelines.
Body size indexing may refine risk. The 2022 ACC/AHA guidelines suggest considering surgery when the aortic cross-sectional area (cm²) to height (m) ratio ≥10 cm²/m 2. This is particularly relevant for patients with small body habitus who may have relatively large aortas despite absolute measurements <5.0 cm.
Surgical risk stratification is essential. The lower thresholds (45 mm) apply specifically to low-risk surgical candidates. In high-risk patients, the risk-benefit calculation shifts toward more conservative management with higher thresholds.
Post-AVR surveillance is mandatory. Even when the ascending aorta is not replaced during initial valve surgery, progressive dilatation can occur. Studies show expansion rates of 0.81 mm/year in patients with baseline dilation 7, and late aortic complications including dissection can occur years after isolated AVR 5.